These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9056582)

  • 21. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach.
    Idkaidek NM; Al-Ghazawi A; Najib NM
    Biopharm Drug Dispos; 2004 Dec; 25(9):367-72. PubMed ID: 15495146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of metabolites in bioequivalence studies: should bioequivalence criteria be applied on the sum of parent compound and metabolite?
    Mahmood I
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):540-4. PubMed ID: 9799058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):105-10. PubMed ID: 2318545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing bioequivalence using genomic data.
    Chow SC; Shao J; Li L
    J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals.
    Esinhart JD; Chinchilli VM
    Int J Clin Pharmacol Ther; 1994 Jan; 32(1):26-32. PubMed ID: 8199749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of bioequivalence using a multiplicative model.
    Chow SC; Peace KE; Shao J
    J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment of bioequivalence].
    Aoyagi N
    Eisei Shikenjo Hokoku; 1996; (114):141-2. PubMed ID: 9037886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar.
    Schall R
    Biometrics; 1995 Jun; 51(2):615-26. PubMed ID: 7662849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The multivariate assessment of bioequivalence.
    Chinchilli VM; Elswick RK
    J Biopharm Stat; 1997 Mar; 7(1):113-23. PubMed ID: 9056592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presentation of results from bioequivalence studies.
    Sauter R; Steinijans VW; Diletti E; Böhm A; Schulz HU
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S7-30. PubMed ID: 1601535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian modeling of multivariate average bioequivalence.
    Ghosh P; Gönen M
    Stat Med; 2008 Jun; 27(13):2402-19. PubMed ID: 18095275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presentation of results from bioequivalence studies.
    Sauter R; Steinijans VW; Diletti E; Böhm A; Schulz HU
    Int J Clin Pharmacol Ther Toxicol; 1992 Jul; 30(7):233-56. PubMed ID: 1506127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
    Bialer M; Midha KK
    Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.